Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying selumetinib to see how well it works in treating patients
with locally advanced or metastatic liver cancer. Selumetinib may stop the growth of tumor
cells by blocking some of the enzymes needed for their growth.